---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-143456"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:28:51.762190+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CalciMedica restates FY2022 financials due to errors in convertible note and warrant valuation

## Summary
- Board concluded Dec 31, 2022 financial statements should no longer be relied upon.
- Errors in valuation of convertible promissory notes and warrant liability; models did not consider merger conversion formula.
- Restatement expected to decrease carrying value of notes and warrant liability, reduce net loss and net loss per share.
- Company plans to file an amended report to reflect corrections; subject to completion of Ernst & Young audit.
- Previously furnished/filed reports describing financial results from Original Report should no longer be relied upon.

## SEC filing metadata
- accession: 0001193125-23-143456
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523143456/0001193125-23-143456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523143456/d491121d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-143456
- JSON: https://secwatch.observer/filing/0001193125-23-143456.json
- Plain text: https://secwatch.observer/filing/0001193125-23-143456.txt

## Key facts
- Auditor Changes
  CalciMedica, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Ernst & Young LLP
  source text: concluded that each of (i) the Company’s financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.1 of the Company’s Form 8-K/A filed on April 4, 2023 (the “Original Report”) with the Securities and Exchange Commission (the “SEC) and (ii) the unaudited pro forma combined financial statements as of and for the year ended December 31, 2022, as included in Exhibit 99.2 of the Original Report (collectively, the “Financial Statements”), should be restated to correct for errors in the valuation of the convertible promissory notes and warrant liability as of December 31, 2022 and accordingly should no longer be relied upon
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312523143456/0001193125-23-143456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.